Skip to main content
About MTPPI
Research
Current Projects
Completed Projects
Research Areas
Causal Inference Toolkit
Publications
Published Research
MTPPI Viewpoint
Resources
Data
Technology
Expertise
Senior Staff
Collaborators
Careers
Contact US
You are here
Home
»
Publications
Published Research
Cotter D, Thamer M, Zhang Y. Thamer M, Ray NF, Richard C, Greer JW, Pearson BC, Cotter DJ. Excluded from universal coverage: ESRD patients not covered by Medicare. Health Care Financ Rev. 1995 Winter;17(2):123-46
Thamer M, Ray NF, Fehrenback SN, Richard C, Kimmel PL. Relative risk and economic consequences of inpatient care among renal failure patients. JASN. 1996;7:751-62.
Cotter DJ, Thamer M, Kimmel PL, Sadler JH. Secular trends in recombinant erythropoietin therapy among the U.S. hemodialysis population: 1990 - 1996.Kidney Int. 1998;54:2129-39.
Thamer M, Richard C, Ray NF, Greer JW, Cotter DJ, Pearson BC. The effect of insurance status on use of recombinant erythropoietin therapy among end-stage renal disease patients in three states. Am J Kidney Dis. 1996 Aug;28(2):235-49.
Ray NF, Thamer M, Taylor T, Fehrenbach SN, Ratner R. Hospitalization and expenditures for the treatment of general medical conditions among the U.S. diabetic population in 1991. J Clin Endocrinol Metab. 1996 Oct;81(10):3671-9.
Thamer M, Richard C, Casebeer AW, Ray NF. Health insurance coverage among foreign-born US residents: the impact of race, ethnicity, and length of residence. Am J Public Health. 1997 Jan;87(1):96-102.
Perry S, Gardner E, Thamer M. The status of health technology assessment worldwide. Results of an international survey. Int J Technol Assess Health Care. 1997 Winter;13(1):81-98.
Melton LJ 3rd, Thamer M, Ray NF, Chan JK, Chesnut CH 3rd, Einhorn TA, Johnston CC, Raisz LG, Silverman SL, Siris ES. Fractures attributable to osteoporosis: report from the National Osteoporosis Foundation. J Bone Miner Res. 1997 Jan;12(1):16-23.
Ray NF, Chan JK, Thamer M, Melton LJ 3rd. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res. 1997 Jan;12(1):24-35.
Perry S, Thamer M.Health technology assessment: decentralized and fragmented in the US compared to other countries. Health Policy. 1997 Jun;40(3):177-98. Corrected and republished in: Health Policy 1997 Dec;42(3):269-90.
Ray NF, Denton WG, Thamer M, Henderson SC, Perry S. Abdominal adhesiolysis: inpatient care and expenditures in the United States in 1994. J Am Coll Surg. 1998 Jan;186(1):1-9.
Thamer M, Fitzpatrick KJ, Perry S. Medical and surgical supply costs. Case study of a costly low-cost technology. Int J Technol Assess Health Care. 1997 Fall;13(4):526-36.
Ray NF, Thamer M, Fadillioglu B, Gergen PJ. Race, income, urbanicity, and asthma hospitalization in California: a small area analysis. Chest. 1998 May;113(5):1277-84
Thamer M, Rinehart C. Public and private health insurance of US foreign-born residents:implications of the 1996 welfare reform law. Ethn Health. 1998 Feb-May;3(1-2):19-29.
Kimmel PL, Thamer M, Richard CM, Ray NF. Psychiatric illness in patients with end-stage renal disease. Am J Med. 1998 Sep;105(3):214-21.
Ray NF, Baraniuk JN, Thamer M, Rinehart CS, Gergen PJ, Kaliner M, Josephs S, Pung YH. Direct expenditures for the treatment of allergic rhinoconjunctivitis in 1996, including the contributions of related airway illnesses. J Allergy Clin Immunol. 1999 Mar;103(3 Pt1):401-7.
Ray NF, Thamer M, Gardner E, Chan JK. Economic consequences of diabetes mellitus in the United States in 1997. Report of the American Diabetes Association. Diabetes Care 1998;21:296-308.
Thamer M, Ray NF, Henderson SC, Rinehart CS, Sherman CR, Ferguson JH. Influence of the NIH Consensus Conference on Helicobacter pylori on physician prescribing among aMedicaid population. Med Care. 1998 May;36(5):646-60.
Thamer M, Brennan N, Semansky R. A cross-national comparison of orphan drug policies:implications for the U.S. Orphan Drug Act. J Health Polit Policy Law. 1998 Apr;23(2):265-90
Thamer M, Chan JK, Ray NF, Vassalotti JA, Kimmel PL. Drug use concomitant with cyclosporine immunosuppressive therapy for 3 years after renal transplantation. Am JKidney Dis. 1998 Feb;31(2):283-92
Thamer M, Henderson SC, Ray NF, Rinehart CS, Greer JW, Danovitch GM. Unequal access to cadaveric kidney transplantation in California based on insurance status. Health Services Res. 1999;34:879-900.
Thamer M, Ray NF, Taylor T. Association between antihypertensive drug use and hypoglycemia: a case-control study of diabetic users of insulin or sulfonylureas. Clin Ther. 1999;21(8):1387-400.
Perry S, Thamer M. Medical innovation and the critical role of health technology assessment.JAMA. 1999 Nov 17;282(19):1869-72.
Gardner EN, Murtaugh CM, Ray NF, Thamer M. The cost of Medicaid-covered services provided to disabled adults with neurologic disorders: implications for managed care. Am J Manag Care. 1999 Nov;5(11):1417-25
Thamer M, Richard CM, Klinkmann J, Ivanovich P, Lang G, Cotter DJ. Use of clinical guidelines for treatment of anemia among hemodialysis patients. Artif Organs. 2000Feb;24(2):91-4
Thamer M, Perry S. Evidence-based assessment of medical technology. JAMA. 2000 Jun 7;283(21):2792-3
Thamer M, Hwang W, Fink NE, Sadler JH, Powe NR. U.S. nephrologists’ recommendation of dialysis modality: Results of a national survey. Am J Kidney Dis. 2000;36:1155-1165.
Thamer M, Hwang W, Fink NE, Sadler JH, Powe NR. U.S. nephrologists’ attitudes towards renal transplantation: Results from a national survey. Transplantation. 2001;71:281-287.
Powe NR, Thamer M, Hwang W, Fink N, Bass EB, Sadler JH, Levin NW. Cost-quality trade-offs in dialysis care: A national survey of dialysis facility administrators. Am J Kidney Dis. 2002;39(1):116-26.
Kimmel PL, Greer JW, Milam RA, Thamer M. Trends in erythropoietin therapy in the U.S. dialysis population: 1995 to 1998. Semin Nephrol. 2000 Jul;20(4):335-44
Estupiñán-Day SR, Baez R, Horowitz H, Warpeha R, Sutherland B, Thamer M. Salt fluoridation and dental caries in Jamaica. Community Dent Oral Epidemiol. 2001 Aug;29(4):247-52
Thamer M, Hwang W, Anderson G. Public support for policies to assist persons with chronic conditions and their caregivers. Health Affairs. 2002;21(4):264-270.
Montenegro-Torres BF, Engelhardt T, Thamer M, Anderson G. Are Fortune 100 companies responsive to chronically ill workers? Health Aff. 2001 Jul-Aug;20(4):209-19
Cotter DJ, Perry S, Thamer M. Technology Assessment at the National Level in the US. Surg Technol Int. 1999;8:45-8
Cotter DJ, Stefanik K, Zhang Y, Thamer M. Improved survival with higher hematocrits: where is the evidence? Semin Dial. 2004 May-Jun;17(3):181-3
Cotter DJ, Stefanik K, Zhang Y, Thamer M, Scharfstein D, Kaufman J. Evaluation of hematocrit as a surrogate endpoint for survival among epoetin-treated hemodialysis patients. J Clin Epidemiol. 2004;57(10):1086-95.
Zhang Y, Thamer M, Stefanik K, Kaufman J, Cotter DJ. Epoetin requirements predict mortality in hemodialysis patients. Am J Kidney Dis. 2004;44(5):866-76.
Thamer M, Zhang Y, Marayati F, Cotter DJ, Kaufman J. Factors influencing route of administration for epoetin treatment among hemodialysis patients in the United States. Am J Kidney Dis. 2006 Jul;48(1):77-87
Cotter D, Thamer M, Narasimhan K, Zhang Y, Bullock K. Translating epoetin research into practice: the role of government and the use of scientific evidence. Health Affairs. 2006;25(5):1249-59.
Thamer M, Zhang Y, Kaufman J, Dong F, Cotter D, Hernan MA. Dialysis facility ownership and epoetin dosing in patients receiving hemodialysis. JAMA. 2007;297(15):1667-74.
Cotter D, Thamer M, Zhang Y, Kaufman J, Hernan MA. The effect of epoetin dose on hematocrit response. Kidney Int. 2008;73(3):347-53.
Zhang Y, Thamer M, Cotter D, Kaufman J, Hernan MA. The estimated effect of epoetin dose on survival among elderly hemodialysis patients in the United States. Clin J Am Soc Nephrol. 2009;4(3):638-44.
Thamer M, Hernán MA, Zhang Y, Cotter D, Michelle P. Relationship between prednisone, lupus activity and permanent organ damage. J Rheumatol. 2009;36(3):560-4
Zhang Y, Thamer M, Cotter D. The effect of dialysis chains on mortality among patients receiving hemodialysis. Health Services Research 2011 Jun;46(3):747-67.
Zhang Y, Thamer M, Kaufman JS, Cotter DJ, Hernán MA. High doses of epoetin do not lower mortality and cardiovascular risk among elderly hemodialysis patients with diabetes. Kidney Int. 2011;80(6):663-669.
Cotter D, Thamer M, Zhang Y. The possible effects of CMS's 'non-decision' on a national coverage decision for ESA therapy. Nephrol News Issues. 2011 Aug;25(9):15-6, 18
Zhang Y, Thamer M, Cotter DJ, Kshirsagar O. Organizational status of dialysis facilities and patient outcome: does higher injectable medication use mediate increased mortality? Health Serv Res. 2013;48:949-71.
Thamer M, Zhang Y, Lai D, Kshirsagar O, Cotter D. Influence of safety warnings on ESA prescribing among dialysis patients using an interrupted time series. BMC Nephrol. 2013;14:172.
Zhang Y, Thamer M, Kaufman J, Cotter D, Hernan M. Comparative effectiveness of two anemia management strategies for complex elderly dialysis patients. Medical Care; in press, January 2014
Other MTPPI Publications :
Diagnostic Imaging
and
Child Abuse:
Technologies,
Practices,
and Guidelines